UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities
Exchange Act of 1934

Filed by the Registrant ☑ 
Filed by a Party other than the Registrant □

Check the appropriate box:

◻
Preliminary Proxy Statement
◻
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
◻
Definitive Proxy Statement
☑
Definitive Additional Materials
◻
Soliciting Material Pursuant to §240.14a-12

IRADIMED CORPORATION
(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

 ☑
No fee required.
   
◻
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
   
 
1)
Title of each class of securities to which transaction applies:
     
     
 
2)
Aggregate number of securities to which transaction applies:
     
     
 
3)
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
     
     
 
4)
Proposed maximum aggregate value of transaction.
     
     
 
5)
Total fee paid:
     
   
 ☐
Fee paid previously with preliminary materials.
 ☐
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration number, or the Form or Schedule and the date of its filing.
     
 
1)
Amount Previously Paid:
     
     
 
2)
Form, Schedule or Registration Statement No.:
     
     
 
3)
Filing Party:
     
     
   4)
Date Filed:
     






IRADIMED CORPORATION
Supplement to Proxy Statement dated April 29, 2020
For the Annual Meeting of Stockholders
To be Held on June 12, 2020



Withdrawal of Director Nominee


This proxy statement supplement, dated June 3, 2020 (the “Supplement”), provides updated information with respect to the 2020 Annual Meeting of Stockholders of IRADIMED CORPORATION (the “Company”) to be held on June 12, 2020 (the “Annual Meeting”).

On or about May 7, 2020, the Company commenced mailing to its stockholders the proxy materials, including the Definitive Proxy Statement for the Annual Meeting (the “Proxy Statement”).  This Supplement describes a recent change in the proposed nominees for election to the Board of Directors of the Company (the “Board”) and replaces and supersedes any inconsistent information set forth in the Proxy Statement.

On May 28, 2020, Leslie McDonnell, the former President and Chief Executive Officer of the Company, separated from the Company.  As a result, Ms. McDonnell’s name has been withdrawn from nomination for re-election to the Board.  The Board has determined that no other nominee for election at the Annual Meeting will be named in place of Ms. McDonnell.

The remaining nominees named in the Proxy Statement will continue to stand for re-election at the Annual Meeting. Notwithstanding Ms. McDonnell’s withdrawal as a nominee for re-election to the Board, the form of proxy card made available with the Notice of the Annual Meeting remains valid; however, any votes that are submitted with instructions to vote for all of the Board’s nominees will be voted only for the remaining four nominees, as named in the Proxy Statement and the instruction to vote for Ms. McDonnell will be disregarded.  If you have already submitted your proxy or provided voting instructions, you do not need to take any action unless you wish to change your vote.  Proxies already submitted by stockholders will remain valid and will be voted at the Annual Meeting, unless revoked as described below.  If you have not yet submitted your proxy or submitted your voting instructions, please disregard Ms. McDonnell’s name as a nominee for election as a director.  None of the other agenda items to be acted upon at the Annual Meeting, which are described in the Proxy Statement, are affected by this Supplement.

If you are a stockholder of record, you may change your vote or revoke your proxy at any time before it is voted at the Annual Meeting by submitting a written notice of revocation, which much be received before the start of the Annual Meeting, addressed to IRADIMED CORPORATION, 1025 Willa Springs Drive, Winter Springs, FL 32708, Attention:  Chris Scott, Corporate Secretary, or by submitting another proxy card before the conclusion of the Annual Meeting.  For all methods of voting, the last vote cast will supersede all previous votes.

If you hold your stock in street name, you may change your vote by: (i) submitting new voting instructions to your broker or other intermediary; or (ii) if you have obtained a legal proxy from your broker or other intermediary, by attending the Annual Meeting and voting in person by written ballot.

    By Order of the Board of Directors,  
       
       


/s/ Chris Scott
  
    Chris Scott
  
    Corporate Secretary
  
       
    June 3, 2020